The sixth edition of ISO 10993-1, released in November 2025, marks a fundamental shift in how the biological safety of medical devices is evaluated. This revision moves the industry decisively away from prescriptive test selection toward a scientifically justified, risk-based biological evaluation strategy embedded within lifecycle risk management.
For manufacturers managing both new developments and legacy portfolios, ISO 10993-1:2025 is not merely an update. It changes how biological risk must be reasoned, documented, and defended.
If you would like to revisit the foundational principles of biological safety and how ISO 10993 structures device evaluation, our article “Understanding ISO 10993: Why Biological Safety Matters in Medical Devices” provides essential context. This analysis builds on that foundation by examining how ISO 10993-1:2025 reshapes the evaluation methodology itself.
Why This Revision Is Structurally Significant
At its core, ISO 10993 has always focused on patient safety, as detailed in the “How Can You Mitigate Risks in Medical Device Development?” ebook from Evalueserve. The 2025 revision strengthens this mission by firmly embedding biological evaluation within risk management principles, consistent with broader regulatory frameworks, such as the EU Medical Device Regulation (MDR).
Historically, many manufacturers relied heavily on Table A.1 to determine required testing based on:
- Nature of body contact
- Contact duration
- Device classification
While practical, this approach often led to conservative over-testing and, more critically, to documentation lacking transparent scientific justification.
ISO 10993-1:2025 reframes biological evaluation as a component of risk management, aligned structurally and philosophically with ISO 14971. Instead of asking “Which tests apply?”, manufacturers must now demonstrate:
- What biological hazards are reasonably foreseeable
- How material characterisation informs exposure
- Whether toxicological thresholds are exceeded
- Why testing is necessary — or scientifically justifiable to omit
This change shifts the emphasis from test execution to defensible toxicological reasoning.
Structural and Conceptual Updates in ISO 10993-1:2025
- Reorganisation Aligned with ISO 14971
The document has been completely reorganised, with the title and overall structure aligned to the risk management framework defined in ISO 14971. This change ensures biological evaluation is fully embedded within a systematic, risk-based approach.
- Clear Guidance on Exposure Duration
New content clarifies how exposure duration should be calculated, supporting more consistent and realistic assessment of biological risk across different device use scenarios.
- Enhanced Device Characterisation and Hazard Identification
Additional guidance has been introduced to support thorough device characterisation and a more robust identification of biological hazards, serving as the foundation for biological risk assessment.
- Revised Identification of Biological Effects
The approach to identifying biological effects (formerly referred to as biological endpoints) has been modified to better reflect clinically relevant biological outcomes.
- Tissue-Specific Contact Terminology
The term “externally communicating” has been replaced with language that explicitly reflects the specific tissue contact of individual device components, improving clarity and precision.
- Broader Application of Local Tissue Effects
“Effects after implantation” has been replaced with “local effects after tissue contact,” recognising that non-implantable devices may also require this type of biological assessment.
- Annex A Refocused on Material Characterisation
Annex A has been revised, with most content incorporated into the main body of the document. The remaining annex content is now focused solely on guiding materials characterisation.
- New Annex B Explaining Biological Effects Updates
A new Annex B has been added to explain the rationale for the revisions to the biological effects listed in Tables 1 to 4, thereby supporting a better understanding and regulatory justification.
What This Means for Manufacturers
The implications are operational, regulatory, and strategic.
Immediate Actions
- Conduct a structured gap assessment of existing BEPs and BERs
- Review extractables and leachables data for adequacy
- Assess legacy devices under updated exposure logic
- Develop an implementation plan for regulatory communication
Manufacturers undergoing EU MDR surveillance or renewal cycles should anticipate early scrutiny of alignment with state-of-the-art standards.
Long-Term Strategic Adjustments
- Fully integrate biological evaluation into the ISO 14971 risk management framework
- Train development and regulatory teams in toxicology-driven justification
- Shift from automatic retesting toward science-based waiver strategies
- Establish lifecycle reassessment protocols for post-market data integration
Critically, ISO 10993-1:2025 does not mandate automatic retesting of legacy devices. However, continued reliance on historical testing without updated scientific justification may create vulnerabilities in the review process.
Regulatory Outlook
Adoption timelines vary by region:
- EU: Under MDR, “state of the art” expectations strongly support adoption, though formal harmonization may take time. Notified Bodies are expected to evaluate implementation pragmatically but rigorously.
- US: FDA recognition is pending; proactive gap analysis remains advisable.
- Japan: Early adoption expectations appear likely.
- Other regions may align with EU positioning.
Open interpretive areas remain, particularly regarding:
- Risk estimation methodologies
- Bioaccumulation thresholds
- Lifecycle data integration
Manufacturers must therefore rely on well-documented scientific rationale where prescriptive clarity is absent.
The Strategic Opportunity Behind the Transition
While the revised standard increases documentation burden, it also offers advantages:
- Reduced unnecessary animal testing
- More efficient testing strategies
- Stronger defensibility during regulatory review
- Greater alignment with modern toxicology science
Organisations that treat ISO 10993-1:2025 as a strategic upgrade — rather than a compliance obstacle — can reduce portfolio risk and improve regulatory predictability.
How Evalueserve IP and R&D Supports ISO 10993-1:2025 Implementation
Evalueserve’s toxicology consulting services team supports clients across the full spectrum of ISO 10993 compliance, including:
- Gap Analysis of existing BEPs and BERs
- Risk-Based Biological Evaluation aligned with ISO 14971
- Toxicology Advisory with strong scientific justification
- Worst Case Assessment for testing strategy
- Regulatory-Ready Documentation for Notified Bodies
- Lifecycle Oversight, including post-market reassessment strategies
Our toxicology and biological safety experts ensure evaluations are scientifically sound, defensible, and regulatory-ready.
Key Takeaway
ISO 10993-1:2025 marks a decisive shift from test-driven compliance to risk-centred, evidence-based biological evaluation. It embeds biocompatibility firmly within lifecycle risk management and elevates expectations for scientific justification.
Manufacturers who act early, perform structured gap assessments, and adopt toxicology-first reasoning will be best positioned to navigate MDR renewals, FDA recognition transitions, and global regulatory convergence.
The era of checklist biocompatibility is closing. The era of defensible risk logic has begun.
